Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
- Conditions
- Obesity or Overweight
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Regor Pharmaceuticals Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT06867718
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC, Norman, Oklahoma, United States
🇺🇸Synexus Clinical Research, Salt Lake City, Utah, United States
🇺🇸Angels Clinical Research, Miami, Florida, United States
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Regor Pharmaceuticals Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06299124
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of RGT001-075 in Adult Patients With Obesity
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Regor Pharmaceuticals Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT06277934
- Locations
- 🇺🇸
Velocity Clinical Research, West Jordan, Utah, United States
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Regor Pharmaceuticals Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05764915
- Locations
- 🇨🇳
The First Affiliated Hospital Of Nanchang University City, Nanchang, Jiangxi, China
🇨🇳Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, Shandong, China
🇨🇳Shanghai East Hospital, Shanghai, Shanghai, China
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: RGT-419B in combination with hormonal therapy
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Regor Pharmaceuticals Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05304962
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸University California, Los Angeles, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
- Prev
- 1
- 2
- Next